Avmapki (avutometinib) - Verastem
Fakzynja (defactinib) - Verastem
AVMAPKI FAKZYNJA CO-PACK (avutometinib in combination with defactinib) U.S. Launch (Businesswire) - Nov 4, 2025 - "Achieved net product revenue of $11.2 million in the first full quarter of the launch." 
Sales • Low Grade Serous Ovarian Cancer
https://www.businesswire.com/news/home/20251104228194/en/Verastem-Oncology-Reports-Third-Quarter-2025-Financial-Results-and-Highlights-Recent-Business-Updates
 
Nov 4, 2025